Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amit Desai

Gastroenterology Dallas, TX Medical Doctor

NPI 1609196179 CMS profile 1006912

8230 Walnut Hill Ln Ste 610, Dallas, TX 75231

Open in the dashboard

General payments

$71,323

444 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$42,321

4 holdings reported · through program year 2025

Through program year 2025, Amit Desai of Dallas, TX is reported in the CMS Open Payments database as having received $71,323 across 444 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $42,321 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63,393 178
2024 General $3,079 119
2023 General $2,665 85
2022 General $1,331 47
2021 General $250 8
2020 General $20 1
2019 General $584 6
2024 Ownership $19,940 1
2023 Ownership $19,940 1
2022 Ownership $1,252 1
2021 Ownership $1,188 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amit Desai
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Amit Desai were reported at $63,393. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Amit Desai Gastroenterology median Middle half National median
2019 $584 $417 $126–$1,100 $163
2020 $20 $224 $74–$624 $114
2021 $250 $352 $106–$1,054 $132
2022 $1,331 $448 $129–$1,270 $149
2023 $2,665 $533 $150–$1,390 $160
2024 $3,079 $605 $160–$1,606 $164
2025 $63,393 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $60,996 78 payments
  2. AbbVie, Inc. $4,102 136 payments
  3. Boston Scientific Corporation $1,261 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $704 44 payments
  5. PENTAX of America, Inc. $457 5 payments
  6. Medtronic, Inc. $337 5 payments
  7. Pfizer Inc. $330 17 payments
  8. Regeneron Healthcare Solutions, Inc. $291 11 payments
  9. Aimmune Therapeutics, Inc. $237 14 payments
  10. Lilly USA, LLC $184 10 payments
  11. Other $2,424 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,134 15 payments
  2. Food and Beverage $11,660 411 payments
  3. Travel and Lodging $6,507 17 payments
  4. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $60,999 73 payments
  2. RINVOQ $1,667 75 payments
  3. SKYRIZI Immunology $1,521 51 payments
  4. SKYRIZI Immunology $802 33 payments
  5. CREON $735 28 payments
  6. ENTYVIO $656 42 payments
  7. STELARA $505 19 payments
  8. LINZESS $486 28 payments
  9. SPYGLASS $310 2 payments
  10. ZENPEP $299 18 payments
  11. Other $5,572 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

454

Median for Gastroenterology: 569

Drug cost

$134,193

Median for Gastroenterology: $104,976

Branded share of claims

35%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 34 $97,963
Linzess Linaclotide Brand 15 $18,578
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 37 $5,929
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 26 $4,243
Cholestyramine Cholestyramine (With Sugar) Brand 33 $2,705
Pantoprazole Sodium Generic 169 $1,730
Omeprazole Generic 101 $1,328
Lubiprostone Generic 12 $803
Cholestyramine Light Cholestyramine Brand 14 $659
Mercaptopurine Generic 13 $256

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$112,056

Medicare's payments for the services billed

Medicare patients

305

Average age 73

Services billed

3,682

152 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 50%
Ischemic heart disease 30%
Diabetes 26%
Depression 21%
Chronic kidney disease 18%
Cancer 18%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $505
$505 — —
CREON
  • AbbVie, Inc. $442
$442 34 —
RINVOQ
  • AbbVie, Inc. $414
$414 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $174
  • GENZYME CORPORATION $89
$263 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $156
$156 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

444 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record